San Antonio Breast Cancer Symposium | Conference

Nab-Paclitaxel Shows Greatest Utility for TNBC

December 8th 2017

Treatment with nab-paclitaxel showed promising improvements in overall survival and progression-free survival compared with standard paclitaxel for patients with metastatic triple-negative breast cancer.

No Difference in Overall Survival with Shorter Extended AI Therapy

December 7th 2017

Investigators with the Austria Breast and Colorectal Cancer Study Group announced today that years can safely be shaved off anastrozole (Arimidex) treatment without affecting disease-free survival postmenopausal HR-positive breast cancer.

Acupuncture Reduces AI-Associated Joint Pain in Women with Breast Cancer

December 7th 2017

A mix of traditional and customized acupuncture techniques proved effective in reducing pain and stiffness associated with aromatase inhibitor (AI) therapy in women with early-stage breast cancer.

1-Year of Adjuvant Trastuzumab Remains Standard in HER2+ Breast Cancer

December 7th 2017

The phase III SOLD trial failed to demonstrate that DFS with 9 weeks of adjuvant trastuzumab was noninferior to the standard 12 months when the 2 regimens were combined with chemotherapy in women with early stage HER2-positive breast cancer.

GnRHa May Protect Ovarian Function, Preserve Fertility in Premenopausal Women With Early-Stage Breast Cancer

December 7th 2017

Results from a meta-analysis of data collected from 837 premenopausal women undergoing chemotherapy for early-stage breast cancer suggest that gonadotropin-releasing hormone analog may preserve fertility and have a protective ovarian function.

Dr. Coombes on Intriguing Results With Celecoxib in Breast Cancer

December 7th 2017

Charles Coombes, MD, professor of medical oncology, Imperial College London, discusses surprising results from a recent study examining celecoxib’s impact on breast cancer progression and relapse.

Dr. Rimawi Discusses the Clinical Need for Immunotherapy in HER2-Positive Breast Cancer

December 7th 2017

Mothaffar F. Rimawi, MD, associate professor and director of clinical research at the Lester and Sue Smith Breast Center at Baylor College of Medicine, discusses the clinical need for immunotherapy regimens for patients with HER2-positive breast cancer.

Ribociclib Improves PFS by 10.8 Months in HR+/HER2- Premenopausal Breast Cancer

December 7th 2017

Newly released results from the MONALEESA-7 trial showed that adding ribociclib to standard endocrine therapy with temporary ovarian suppression significantly improved progression-free survival as a first-line treatment for pre- and perimenopausal women with advanced HR-positive/HER2-negative breast cancer.

Dr. Nangia Discusses the Logistics of Implementing a Scalp Cooling System

December 7th 2017

Julie R. Nangia, MD, assistant professor of medicine, Baylor College of Medicine, discusses some logistical factors that oncologists and health care providers should know regarding implementing a scalp cooling system.

Pembrolizumab/Trastuzumab Active in HER2-Positive Breast Cancer

December 7th 2017

The combination of pembrolizumab and trastuzumab reached an objective response rate of 15.2% in patients with trastuzumab-resistant, PD-L1–positive, HER2-positive breast cancer.

Alternative Chemotherapy Dosing Strategies Improve Breast Cancer Outcomes

December 6th 2017

Shortening the intervals between chemotherapy cycles or administering the drugs sequentially reduced early-stage breast cancer recurrence and mortality compared with standard dosing techniques.

Sacituzumab Govitecan Highly Effective in Heavily Pretreated mTNBC

December 6th 2017

Treatment with sacituzumab govitecan elicited an objective response rate of 34% in patients with heavily pretreated metastatic triple-negative breast cancer.

Trastuzumab Disappoints in HER2-low Patient Cohort

December 6th 2017

A trial to determine the value of trastuzumab plus standard adjuvant chemotherapy in patients with low levels of HER2 protein has shown no significant efficacy, confounding investigators who launched the trial based on opposing results from 2 earlier studies.

Dual HER2-Blockade Plus AI Shows Promise in HER2+/ER+ Breast Cancer

January 17th 2017

Data from the phase II PERTAIN trial presented late last year at the 2016 San Antonio Breast Cancer Symposium showed that adding an aromatase inhibitor (AI) to pertuzumab and trastuzumab extended progression-free survival by over 3 months versus trastuzumab plus an AI in patients with HER2-positive, HR-positive locally advanced or metastatic breast cancer.

Pegram Sheds Light on Margetuximab in HER2+ Breast Cancer

January 14th 2017

The Fc-modified monoclonal antibody margetuximab in combination with chemotherapy may offer a new treatment option for patients with HER2-positive metastatic breast cancer.

Prophylactic Treatment Reduces Neratinib-Related Toxicity in HER2+ Breast Cancer

January 5th 2017

A prophylactic treatment of loperamide plus budesonide reduced the rate of grade 3 diarrhea associated with neratinib.

Dr. Brufsky on Cobimetinib Plus Paclitaxel in TNBC

January 4th 2017

Adam M. Brufsky, MD, PhD, professor of Medicine, associate chief of Hematology/Oncology, co-director of the Comprehensive Breast Care Center, associate director of Clinical Investigation, University of Pittsburgh, discusses combining cobimetinib and paclitaxel as a first-line treatment in patients with advanced triple-negative breast cancer.

Post-Mastectomy Radiation Associated With Increased Complications for Some Patients

December 22nd 2016

Patients with breast cancer who received radiation therapy after undergoing a mastectomy reported increased complications and lower satisfaction.

Hurvitz Sheds Light on Abemaciclib Activity in HR+/HER2- Breast Cancer

December 20th 2016

The neoadjuvant combination of CDK4/6 inhibitor abemaciclib plus anastrazole may represent a novel therapeutic option for patients with hormone receptor-positive, HER2-negative early breast cancer.

Axillary Lymph Node Dissection Can Be Avoided for Some Patients With Breast Cancer, Study Shows

December 19th 2016

Results of a clinical trial show that an axillary lymph node dissection can be avoided for patients with large, operable tumors in the breast, no clinical signs of cancer in the axillary nodes before being treated with neoadjuvant chemotherapy, and no signs of cancer following a sentinel lymph node biopsy during surgery.